Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review

The use of the vaccine in Asia is still very much limited and remained controversial due to its safety, which has yet been properly assessed and evaluated. Hence, the objective of this review is to assess the safety of the CYD-TDV dengue vaccine of the efficacy trials conducted in Asia. A total of 3...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	W. R. Wan Ismail, M. Sh. Abdul Majid, H. Y. Li, M. F. Madrim, S.Sh. S. Abdul Rahim, M. S. Jeffree, Z. I. Azhar, H. F. Ghazi, M. R. Hassan
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2021
Materias:	dengue vaccine cyd-tdv safety adults children asia Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/2380e5bf1b174ed8b3dcfca47d1772bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2380e5bf1b174ed8b3dcfca47d1772bf
record_format	dspace
spelling	oai:doaj.org-article:2380e5bf1b174ed8b3dcfca47d1772bf2021-11-22T07:09:54ZSafety of dengue vaccine (CYD-TDV) in Asia: a systematic review2220-76192313-739810.15789/2220-7619-SOD-1297https://doaj.org/article/2380e5bf1b174ed8b3dcfca47d1772bf2021-06-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1297https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398The use of the vaccine in Asia is still very much limited and remained controversial due to its safety, which has yet been properly assessed and evaluated. Hence, the objective of this review is to assess the safety of the CYD-TDV dengue vaccine of the efficacy trials conducted in Asia. A total of 309 related articles were generated from the electronic database search using relevant keywords and only four of the articles were selected for the final review process. The seroprevalence at baseline of the participants involved in the studies was between 50 percent and 80 percent. In terms of the safety of the CYD-TDV vaccine, injection site reaction (pain, swelling, erythema) recorded a relative risk (RR) at 95% CI of (0.46—1.76) and systemic reactions (fever, headache, myalgia) also with RR at 95% CI of (0.89—1.81) were detected among the participants. Among the four studies reviewed, three studies reported some severe adverse effect experienced by the participants with RR at 95% CI of (0.92—2.11). In terms of the immunogenicity, high GMT values were reported for DENV-2 at 67.8 (95%CI of 64.8-70.8), DENV-3 at 73.1 (95% CI of 69.9-76.3) and DENV-4 at 65 (95%CI of 62-67.9) where even though lower values were reported it is consistent with other published studies on the immunogenicity of the CYD-TDV against the DENV serotypes. This review showed that the CYD-TDV can be considered for use in Asia, but with several conditions and following current safety recommendations.W. R. Wan IsmailM. Sh. Abdul MajidH. Y. LiM. F. MadrimS.Sh. S. Abdul RahimM. S. JeffreeZ. I. AzharH. F. GhaziM. R. HassanSankt-Peterburg : NIIÈM imeni Pasteraarticledengue vaccinecyd-tdvsafetyadultschildrenasiaInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 11, Iss 3, Pp 447-453 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	dengue vaccine cyd-tdv safety adults children asia Infectious and parasitic diseases RC109-216
spellingShingle	dengue vaccine cyd-tdv safety adults children asia Infectious and parasitic diseases RC109-216 W. R. Wan Ismail M. Sh. Abdul Majid H. Y. Li M. F. Madrim S.Sh. S. Abdul Rahim M. S. Jeffree Z. I. Azhar H. F. Ghazi M. R. Hassan Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review
description	The use of the vaccine in Asia is still very much limited and remained controversial due to its safety, which has yet been properly assessed and evaluated. Hence, the objective of this review is to assess the safety of the CYD-TDV dengue vaccine of the efficacy trials conducted in Asia. A total of 309 related articles were generated from the electronic database search using relevant keywords and only four of the articles were selected for the final review process. The seroprevalence at baseline of the participants involved in the studies was between 50 percent and 80 percent. In terms of the safety of the CYD-TDV vaccine, injection site reaction (pain, swelling, erythema) recorded a relative risk (RR) at 95% CI of (0.46—1.76) and systemic reactions (fever, headache, myalgia) also with RR at 95% CI of (0.89—1.81) were detected among the participants. Among the four studies reviewed, three studies reported some severe adverse effect experienced by the participants with RR at 95% CI of (0.92—2.11). In terms of the immunogenicity, high GMT values were reported for DENV-2 at 67.8 (95%CI of 64.8-70.8), DENV-3 at 73.1 (95% CI of 69.9-76.3) and DENV-4 at 65 (95%CI of 62-67.9) where even though lower values were reported it is consistent with other published studies on the immunogenicity of the CYD-TDV against the DENV serotypes. This review showed that the CYD-TDV can be considered for use in Asia, but with several conditions and following current safety recommendations.
format	article
author	W. R. Wan Ismail M. Sh. Abdul Majid H. Y. Li M. F. Madrim S.Sh. S. Abdul Rahim M. S. Jeffree Z. I. Azhar H. F. Ghazi M. R. Hassan
author_facet	W. R. Wan Ismail M. Sh. Abdul Majid H. Y. Li M. F. Madrim S.Sh. S. Abdul Rahim M. S. Jeffree Z. I. Azhar H. F. Ghazi M. R. Hassan
author_sort	W. R. Wan Ismail
title	Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review
title_short	Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review
title_full	Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review
title_fullStr	Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review
title_full_unstemmed	Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review
title_sort	safety of dengue vaccine (cyd-tdv) in asia: a systematic review
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2021
url	https://doaj.org/article/2380e5bf1b174ed8b3dcfca47d1772bf
work_keys_str_mv	AT wrwanismail safetyofdenguevaccinecydtdvinasiaasystematicreview AT mshabdulmajid safetyofdenguevaccinecydtdvinasiaasystematicreview AT hyli safetyofdenguevaccinecydtdvinasiaasystematicreview AT mfmadrim safetyofdenguevaccinecydtdvinasiaasystematicreview AT sshsabdulrahim safetyofdenguevaccinecydtdvinasiaasystematicreview AT msjeffree safetyofdenguevaccinecydtdvinasiaasystematicreview AT ziazhar safetyofdenguevaccinecydtdvinasiaasystematicreview AT hfghazi safetyofdenguevaccinecydtdvinasiaasystematicreview AT mrhassan safetyofdenguevaccinecydtdvinasiaasystematicreview
_version_	1718417905055432704

Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review

Ejemplares similares